IXC
$8M32mo
Invex Therapeutics
Biotechnology · Neurology
Developing Presendin (repurposed drug) for idiopathic intracranial hypertension (IIH). Phase 3 trial terminated early; reassessing strategy.
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$4.6M
Dec 2025 4C
Runway
32moSTABLE
Based on Dec 2025 4C
Market Cap
$8M
Burn Rate
$0.4M/qtr
Dec 2025 4C
Shares Outstanding
75M
Pipeline Assets
1
Latest Insight(1)
12 Feb 2026Half YearAppendix 4D and Half Year Report
Cash$4.6M·Burn$0.8M/q·OCF$-0.8M
3M Price
IXC.ASX$0.100-13.0% 3M
Low $0.090High $0.130
Pipeline Assets (1)
PresendinIdiopathic intracranial hypertension
Phase 3Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Presendin
Idiopathic intracranial hypertension
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
3 competitor trialsPhase 2+ · Non-ASX
Idiopathic Intracranial Hypertension3 active trials
1 Ph42 Ph3
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (2)· 1 upcoming · 1 past
Presendin IP/asset divestment or licensing deal
UpcomingSpeculativearrow_upwardHigh31 Dec 2026
expand_more1 past catalyst
Completed
Confirmedarrow_upwardHigh13 Apr 2026
Results available at https://clinicaltrials.gov/study/NCT05347147
| Event | Type |
|---|
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filed 1 of 1 4Cs on time· statutory deadline
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Announcements(5)
payments
Quarterly 4CPSauto_awesome
Quarterly Activities/Appendix 4C Cash Flow Report22 Jan 2026
expand_more988KB